The PennZone

  • Home
  • Non-profit
  • Health
  • Books
  • Business
  • Entertainment
  • Legal
  • Marketing
  • Sports

Planned Spin-Out to Focus on Gene Therapy for Type 1 and 2 Diabetes in Parallel to Treatments for Late Stage Lung Cancer: Genprex: Stock Symbol: GNPX
The PennZone/10280925

Trending...
  • Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
  • New Bethany, Provident Bank, Jaindl Farms and Lehigh Valley IronPigs Unite for Turkey Drive
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
GNPX NASDAQ NASDAQ: GNPX Genprex, Inc Stock Symbol: GNPX Corporate Ads
Genprex Stock Symbol: GNPX is Gene Therapy Focused on Life-Changing Developments for Cancer and Diabetes

AUSTIN, Texas - PennZone -- Genprex, Inc. (Stock Symbol: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. GNPX technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. GNPX works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The GNPX oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor.

The GNPX lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of GNPX lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and the GNPX SCLC program has received an FDA Orphan Drug Designation. The GNPX diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

More on The PennZone
  • 6,238 executives took new roles at US nonprofits from June to October 2026
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
  • LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
  • Woodside Village Joins Corner Property Management Following CMP Acquisition
  • 20-Year Crash Cost of Signalized RC3 Cloverleaf Could Exceed $25 Million

Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

On September 4th GNPX announced its intention to transfer the Company's diabetes clinical development program and its diabetes gene therapy assets into a new, wholly-owned subsidiary ("NewCo"). NewCo would focus on developing and commercializing GPX-002, a diabetes gene therapy drug candidate for the treatment of Type 1 (T1D) and Type 2 diabetes (T2D). This decision was made public on September 4, 2024.

The planned spin-out transaction would allow both GNPX and NewCo to enhance each company's focus on meeting the needs of their respective markets, patients and stakeholders. The GNPX spin-out, would result in NewCo focusing on developing GPX-002, while GNPX would retain its oncology clinical development programs and other oncology pipeline assets. The decision to pursue the reorganization demonstrates a strong ongoing commitment to the GNPX streamlined, focused strategies and ongoing research and development prioritization initiative.  The potential formation and transfer of the clinical development program into the wholly-owned subsidiary is currently anticipated to occur by the end of 2024.

The GNPX goal for separating the diabetes clinical development program from its oncology program follows closely behind a recent announcement to re-focus the GNPX oncology clinical development program for streamlined, expeditious regulatory submission of its lead oncology drug candidate, Reqorsa® Gene Therapy.  As previously announced, GNPX continues to evaluate ways to optimize its clinical and research programs and operational strategies.  Additionally, GNPX is considering various strategic alternatives and opportunities to enhance stockholder value.

Presentations to Highlight Gene Therapies for Cancer and Diabetes

More on The PennZone
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
  • BitTitan Expands MigrationWiz with SharePoint Sites Migration and Simplified Collaboration Licensing
  • Olympic champion Katie Moon to compete at Pole Vault in Paradise in Key West
  • Smith Strong Merges With Gravis Law, Bringing Gravis Law to Virginia

GNPX
has announced its participation in the following upcoming investor and industry conferences:

Event: H.C. Wainwright 26th Annual Global Investment Conference
Conference Dates: September 9-13, 2024
Presentation Date: On-demand September 9-11, 2024 in the conference portal (virtual)

Event: Chardan's 8th Annual Genetic Medicines Conference
Dates: September 30 – October 1, 2024
Location: Westin Grand Central in New York, NY

New Video Featuring GNPX Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

On August 15th GNPX released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the GNPX oncology clinical development program.

To watch the video, visit the GNPX website at: https://www.genprex.com/videos/.

The Acclaim-1 clinical trial is evaluating the combination of the GNPX lead drug candidate, Reqorsa® Gene Therapy, and AstraZeneca's Tagrisso® to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso.

The Acclaim-3 clinical trial is evaluating the combination of REQORSA and GNPX Tecentriq® as a maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.

Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: media@genprex.com
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website

Contact
Corporate Ads
***@gmail.com


Source: Corporate Ads
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props
  • Kitchen Table Economics: An Invitation to Think Differently
  • New Bethany, Provident Bank, Jaindl Farms and Lehigh Valley IronPigs Unite for Turkey Drive
  • Grace Montessori School Awarded $56,180 to Support Scholarships for 15 Students
  • Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
  • CB Stuffer Announces Private Sale to Secure Future of Brand Growth
  • Brother Marcus Celebrates 400th Episode of The Elements of Inspiration Podcast
  • USA Dental Edge Unveils Dental Intelligence
  • The Fifth Annual "Bamboo Lantern Festival" to Illuminate Tokyo Mizumachi and Sumida River Walk®
  • Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
  • Searching for the Next LBE Creator: CalArts Launches First-Ever D.R.E.A.M.S. Pitch Competition
  • TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
  • An AI Plays Kenshi Entirely by Itself, Live 23 Hours a Day, With an AI Host and Chat Voting
  • Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains
  • Philadelphia-Area Entrepreneur Nouho M Kanneh Builds $37 Million Net Worth Across Real Estate, E-Commerce and Retail
  • Meals on Wheels of the Greater Lehigh Valley Raises Over $50,000 to Help Feed Local Seniors
  • Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices

Popular on PennZone

  • ASSIST Software Wins Volkswagen Challenge for Automated Quality Inspection - 177
  • ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs - 166
  • Hunter's Garage Teams Up With The Small Batch for a Free Thanksgiving Meal - 161
  • What Mold Remediation Costs in Gettysburg, PA: 2026 Price Ranges by Job Type - 154
  • New Children's Picture Book "Adam's Apple" Celebrates Childhood Curiosity and the Funny Misundersta - 138
  • New Children's Picture Book "Tippy Tay" Explores the Dangers of Peer Pressure and the Importance of - 135
  • WebDrafter Welcomes Dreamwork Exteriors as a New Marketing Client - 131
  • Sycamore Dove Releases "Loving Every Moment" - 120
  • Conservative Latinos for PA PAC Endorses Stacy Garrity for Governor: "Pennsylvania's Latino Families Need a Leader Who Delivers" - 106
  • Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders

Similar on PennZone

  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • Kitchen Table Economics: An Invitation to Think Differently
  • TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
  • Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us